99248-33-6
Chemical Structure
Seglitide acetate
Synonym(s): MK 678 acetate; L 36358 acetate
- CAS No.: 99248-33-6
- Formula:C46H60N8O9
- Molecular Weight:869.02
IUPAC Name: (3S,6S,9S,12R,15S,18S)-12-((1H-indol-3-yl)methyl)-9-(4-aminobutyl)-3-benzyl-15-(4-hydroxybenzyl)-6-isopropyl-1,18-dimethyl-1,4,7,10,13,16-hexaazacyclooctadecane-2,5,8,11,14,17-hexaone acetate
InChIKey: FIKSSPSBVSPVFU-WIKDFEFZSA-N
SMILES: CC(O)=O.O=C([C@@H](NC([C@@H](N(C([C@@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)C)=O)CC2=CC=CC=C2)=O)C)C)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45
Biological Activity: Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Seglitide acetate | 98.76% | Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Dimech J, et al. Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria. Br J Pharmacol. 1993 Aug;109(4):898-9. [Content Brief]
- [2]. Bhattarai J P, Kaszas A, Park S A, et al. Somatostatin inhibition of gonadotropin-releasing hormone neurons in female and male mice[J]. Endocrinology, 2010, 151(7): 3258-3266. [Content Brief]
- [3]. Hartmann J, et al. Blood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678. Life Sci. 1989;45(3):267-74. [Content Brief]
Keywords
